Literature DB >> 19602340

Partial fasciectomy for Dupuytren's contractures.

Andreas F Mavrogenis1, Sarantis G Spyridonos, Ioannis A Ignatiadis, Dimitrios Antonopoulos, Panayiotis J Papagelopoulos.   

Abstract

One hundred ninety-six patients with Dupuytren's contractures were treated by partial fasciectomy and adequate postoperative rehabilitation. All patients had flexion contracture of the proximal interphalangeal joint of >20 degrees ; 93 patients had flexion contracture of the associated metacarpophalangeal joint of >30 degrees ; 143 patients had risk factors for Dupuytren's disease. Primary skin closure and splinting were done in all patients. Range of motion was begun by the 1st week. Splinting was discontinued by the 2nd week, followed by night-time splinting until the 8th week. The mean follow-up was 6.6 years (range, 2-9 years). At the latest examination, 72.5% of the patients had complete range of motion of the metacarpophalangeal and proximal interphalangeal joints; 20.2% had 5 degrees -10 degrees of extension deficit and 7.3% had recurrent contractures of >20 degrees at the proximal interphalangeal joint and were subjected to reoperation. Complications included digital neurovascular injury in 5%, complex regional pain syndrome in 10.1%, and wound-healing problems and superficial infections in 15.1%.

Entities:  

Mesh:

Year:  2009        PMID: 19602340

Source DB:  PubMed          Journal:  J Surg Orthop Adv        ISSN: 1548-825X


  7 in total

1.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

2.  Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren's contracture.

Authors:  Nash H Naam
Journal:  Hand (N Y)       Date:  2013-12

Review 3.  Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.

Authors:  Catherine Ball; Anna L Pratt; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2013-04-10       Impact factor: 2.362

Review 4.  What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practice.

Authors:  Anna L Pratt; Catherine Ball
Journal:  BMC Musculoskelet Disord       Date:  2016-01-13       Impact factor: 2.362

5.  Phalangeal Fracture During Attempted Dupuytrens Release Following Clostridial Collagenase Injection: Case Report.

Authors:  Laura W Lewallen; Marco Rizzo
Journal:  J Orthop Case Rep       Date:  2017 Jul-Aug

6.  RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease.

Authors:  Scott M Riester; Diren Arsoy; Emily T Camilleri; Amel Dudakovic; Christopher R Paradise; Jared M Evans; Jorge Torres-Mora; Marco Rizzo; Peter Kloen; Marianna Kruithof-de Julio; Andre J van Wijnen; Sanjeev Kakar
Journal:  BMC Med Genomics       Date:  2015-10-07       Impact factor: 3.063

Review 7.  Connective Tissue Degeneration: Mechanisms of Palmar Fascia Degeneration (Dupuytren's Disease).

Authors:  S Karkampouna; M Kreulen; M C Obdeijn; P Kloen; A L Dorjée; F Rivellese; A Chojnowski; I Clark; Marianna Kruithof-de Julio
Journal:  Curr Mol Biol Rep       Date:  2016-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.